Evidence map›Paper›PMID 35365713›Full record

Trial reportScientific reports2022

Strain-resolved analysis in a randomized trial of antibiotic pretreatment and maintenance dose delivery mode with fecal microbiota transplant for ulcerative colitis.

Byron J Smith, Yvette Piceno, Martin Zydek, Bing Zhang, Lara Aboud Syriani, Jonathan P Terdiman, Zain Kassam, Averil Ma, Susan V Lynch, Katherine S Pollard and 1 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03006809 (Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis), which is not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03006809 phase1completednot on this map

Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis

TypeinterventionalSponsorNajwa ElnachefRan2017 to 2021Enrolled30ConditionsUlcerative ColitisArmsFecal Microbiota Transplantation (FMT), OpenBiome, pretreatment antibiotics
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. A prevalent huge phage clade in human and animal gut microbiomes.bioRxiv : the preprint server for biology · 2025
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Byron J SmithGladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA.ORCID 0000-0002-0182-404X
Yvette PicenoSymbiome, Inc., San Francisco, CA, USA.
Martin ZydekDivision of Gastroenterology, University of California, San Francisco, CA, USA.
Bing ZhangDivision of Gastroenterology, University of California, San Francisco, CA, USA.
Lara Aboud SyrianiCollege of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA.
Jonathan P TerdimanDivision of Gastroenterology, University of California, San Francisco, CA, USA.
Zain KassamFinch Therapeutics, Somerville, MA, USA.
Averil MaDepartment of Medicine, University of California, San Francisco, CA, USA.ORCID 0000-0003-4817-1258
Susan V LynchDivision of Gastroenterology, University of California, San Francisco, CA, USA.ORCID 0000-0001-5695-7336
Katherine S PollardGladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA. katherine.pollard@gladstone.ucsf.edu.
Najwa El-NachefDivision of Gastroenterology, University of California, San Francisco, CA, USA. najwa.elnachef@ucsf.edu.
University of California, San Francisco · USGladstone Institutes · USFinch Therapeutics (United States) · USUniversity of Southern California · USWestern University of Health Sciences · US

Funding

TRAINING PROGRAM IN DISGESTIVE DISEASES AND NUTRITIONT32DK007007 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AVERIL I MA · 1986 to 2026
$6.4M
NIDDK NIH HHS T32 DK007007NIH HHS 5T32DK007007
6 · The paper itself

Abstract

Fecal microbiota transplant is a promising therapy for ulcerative colitis. Parameters maximizing effectiveness and tolerability are not yet clear, and it is not known how import the transmission of donor microbes to patients is. Here (clinicaltrails.gov: NCT03006809) we have tested the effects of antibiotic pretreatment and compared two modes of maintenance dose delivery, capsules versus enema, in a randomized, pilot, open-label, 2 × 2 factorial design with 22 patients analyzed with mild to moderate UC. Clinically, the treatment was well-tolerated with favorable safety profile. Of patients who received antibiotic pretreatment, 6 of 11 experienced remission after 6 weeks of treatment, versus 2 of 11 non-pretreated patients (log odds ratio: 1.69, 95% confidence interval: -0.25 to 3.62). No significant differences were found between maintenance dosing via capsules versus enema. In exploratory analyses, microbiome turnover at both the species and strain levels was extensive and significantly more pronounced in the pretreated patients. Associations were also revealed between taxonomic turnover and changes in the composition of primary and secondary bile acids. Together these findings suggest that antibiotic pretreatment contributes to microbiome engraftment and possibly clinical effectiveness, and validate longitudinal strain tracking as a powerful way to monitor the dynamics and impact of microbiota transfer.

Indexed as

Colitis, UlcerativeGastrointestinal MicrobiomeAnti-Bacterial AgentsFecal Microbiota TransplantationFecesHumansRemission InductionAnti-Bacterial Agents

Identifiers

PMID35365713
PMCPMC8976058
OpenAlexW4220978744

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.